MoonLake Immun还原疗法在药物试验失败后面临调查,导致89%的库存下降。 MoonLake Immunotherapeutics faces investigation after its drug trial failed, causing an 89% stock drop.

月湖免疫疗法公司 (NASDAQ:MLTX) 正在接受多家律师事务所的调查,包括DJS律师事务所,沙尔律师事务所和罗森律师事务所, 涉及潜在的证券法违法行为. MoonLake Immunotherapeutics (NASDAQ: MLTX) is under investigation by multiple law firms, including DJS Law Group, Schall Law Firm, and The Rosen Law Firm, over potential securities law violations. 该公司于2025年9月29日披露, VELA-2临床试验因安慰剂组出乎意料的意外事件而未能达到其主要终点,导致库存下降89%至90%。 The probe follows the company’s September 29, 2025, disclosure that its VELA-2 clinical trial failed to meet its primary endpoint due to unexpected events in the placebo group, causing the stock to drop 89% to 90%. 调查人员正在调查MoonLake是否在宣布前对审判前景作了误导性或不完整的陈述,从而有可能误导投资者。 Investigators are examining whether MoonLake made misleading or incomplete statements about the trial’s prospects prior to the announcement, potentially misleading investors. 受影响的股东可能有资格参加集体诉讼诉讼,要求获得赔偿,无需预付费用。 Affected shareholders may be eligible to join a class action lawsuit seeking compensation, with no upfront costs.